Share on StockTwits

Boston Scientific (NYSE:BSX) EVP Michael P. Phalen unloaded 13,500 shares of Boston Scientific stock in a transaction dated Tuesday, April 15th. The stock was sold at an average price of $13.25, for a total transaction of $178,875.00. Following the transaction, the executive vice president now directly owns 127,486 shares of the company’s stock, valued at approximately $1,689,190. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Boston Scientific (NYSE:BSX) traded up 1.11% during mid-day trading on Thursday, hitting $13.65. 8,675,932 shares of the company’s stock traded hands. Boston Scientific has a 52-week low of $7.07 and a 52-week high of $14.08. The stock has a 50-day moving average of $13.24 and a 200-day moving average of $12.5. The company’s market cap is $18.075 billion.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Tuesday, February 4th. The company reported $0.21 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.13 by $0.08. The company had revenue of $1.84 billion for the quarter, compared to the consensus estimate of $1.83 billion. During the same quarter last year, the company posted $0.18 earnings per share. Boston Scientific’s revenue was up .9% compared to the same quarter last year. Analysts expect that Boston Scientific will post $0.78 EPS for the current fiscal year.

A number of research firms have recently commented on BSX. Analysts at Bank of America upgraded shares of Boston Scientific from a “neutral” rating to a “buy” rating in a research note on Monday. They now have a $16.00 price target on the stock, up previously from $15.00. They noted that the move was a valuation call. Separately, analysts at BofA Merrill Lynch raised their price target on shares of Boston Scientific from $7.00 to $9.00 in a research note on Monday. They now have a “buy” rating on the stock. Finally, analysts at UBS AG raised their price target on shares of Boston Scientific from $12.00 to $15.00 in a research note on Monday, March 24th. They now have an “outperform” rating on the stock. Eight investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Boston Scientific presently has an average rating of “Buy” and a consensus target price of $12.97.

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.